Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
95,714,968
-
Total 13F shares
-
59,826,628
-
Share change
-
+386,824
-
Total reported value
-
$2,811,325,020
-
Put/Call ratio
-
179%
-
Price per share
-
$46.98
-
Number of holders
-
407
-
Value change
-
+$6,501,203
-
Number of buys
-
167
-
Number of sells
-
196
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2024
As of 30 Sep 2024,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
407 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,826,628 shares.
The largest 10 holders included
Capital International Investors, ARK Investment Management LLC, STATE STREET CORP, Sumitomo Mitsui Trust Group, Inc., Nikko Asset Management Americas, Inc., BlackRock, Inc., T. Rowe Price Investment Management, Inc., FMR LLC, VANGUARD GROUP INC, and NEA Management Company, LLC.
This page lists
407
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.